Inclusion Criteria:  Patients with locally advanced non-small cell lung cancer (stage II or III) and thoracic esophageal squamous cell carcinoma (CT2N1-2M0, CT3-4AN0-2M0). Preoperative biopsy pathology confirmed squamous cell carcinoma or adenocarcinoma with negative driver gene. Without any anti-tumor therapy. Endoscopic examination indicated that the midpoint of the tumor was located in the middle and lower esophageal thoracic segments. Preoperative staging is II or III. Ages 18 to 72 years. Cardiopulmonary, liver and kidney function tests can tolerate surgery. ECOG PS 0-1. Signed the informed consent to participate in the study plan before enrollment.  Exclusion Criteria:  Preoperative endoscopic biopsy pathology confirmed small cell carcinoma. Has undergone other anti-tumor therapy. Endoscopic examination indicated that the midpoint of the tumor was located in the upper part of the esophagus. Preoperative examination suggested that T4B was unresectable or distantly metastatic. Corticosteroids or other immunosuppressive drugs were used within 14 days before enrollment. Topical substitute steroids (daily dose ≤10mg) or short-term prescription corticosteroids (≤7 days) were allowed for the prevention or treatment of non-autoimmune diseases. A history of active autoimmune disease or a possible recurrence of autoimmune disease. Severe chronic or active infectious disease. History of interstitial lung disease.